112 related articles for article (PubMed ID: 24399357)
1. SUMOylation alterations are associated with multidrug resistance in hepatocellular carcinoma.
Qin Y; Bao H; Pan Y; Yin M; Liu Y; Wu S; Li H
Mol Med Rep; 2014 Mar; 9(3):877-81. PubMed ID: 24399357
[TBL] [Abstract][Full Text] [Related]
2. Small ubiquitin-related modifier 1 is involved in hepatocellular carcinoma progression via mediating p65 nuclear translocation.
Liu J; Tao X; Zhang J; Wang P; Sha M; Ma Y; Geng X; Feng L; Shen Y; Yu Y; Wang S; Fang S; Shen Y
Oncotarget; 2016 Apr; 7(16):22206-18. PubMed ID: 26993772
[TBL] [Abstract][Full Text] [Related]
3. Interplay between SUMO1-related SUMOylation and phosphorylation of p65 promotes hepatocellular carcinoma progression.
Jiang C; Zhang C; Dai M; Wang F; Xu S; Han D; Wang Y; Cao Y; Liang Y; Zhang Z; Yan L; Shen Y; He K; Shen Y; Liu J
Biochim Biophys Acta Mol Cell Res; 2024 Jan; 1871(1):119595. PubMed ID: 37730133
[TBL] [Abstract][Full Text] [Related]
4. Increased Small Ubiquitin-like Modifier-Activating Enzyme SAE1 Promotes Hepatocellular Carcinoma by Enhancing mTOR SUMOylation.
Chen Y; Peng W; Tao Q; Li S; Wu Z; Zhou Y; Xu Q; Shu Y; Xu Y; Shao M; Chen M; Shi Y
Lab Invest; 2023 Jan; 103(1):100011. PubMed ID: 36748193
[TBL] [Abstract][Full Text] [Related]
5. SUMO1 modification of methyltransferase-like 3 promotes tumor progression via regulating Snail mRNA homeostasis in hepatocellular carcinoma.
Xu H; Wang H; Zhao W; Fu S; Li Y; Ni W; Xin Y; Li W; Yang C; Bai Y; Zhan M; Lu L
Theranostics; 2020; 10(13):5671-5686. PubMed ID: 32483411
[No Abstract] [Full Text] [Related]
6. Small ubiquitin-related modifier 2/3 interacts with p65 and stabilizes it in the cytoplasm in HBV-associated hepatocellular carcinoma.
Liu J; Sha M; Wang Q; Ma Y; Geng X; Gao Y; Feng L; Shen Y; Shen Y
BMC Cancer; 2015 Oct; 15():675. PubMed ID: 26458400
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the JNK signaling pathway increases sensitivity of hepatocellular carcinoma cells to cisplatin by down-regulating expression of P-glycoprotein.
Liu XY; Liu SP; Jiang J; Zhang X; Zhang T
Eur Rev Med Pharmacol Sci; 2016; 20(6):1098-108. PubMed ID: 27049263
[TBL] [Abstract][Full Text] [Related]
8. Speckle-type POZ protein suppresses hepatocellular carcinoma cell migration and invasion via ubiquitin-dependent proteolysis of SUMO1/sentrin specific peptidase 7.
Ji P; Liang S; Li P; Xie C; Li J; Zhang K; Zheng X; Feng M; Li Q; Jiao H; Chi X; Zhao W; Zhang S; Wang X
Biochem Biophys Res Commun; 2018 Jul; 502(1):30-42. PubMed ID: 29777712
[TBL] [Abstract][Full Text] [Related]
9. Overexpressed nuclear BAG-1 in human hepatocellular carcinoma is associated with poor prognosis and resistance to doxorubicin.
Ni W; Chen B; Zhou G; Lu C; Xiao M; Guan C; Zhang Y; He S; Shen A; Ni R
J Cell Biochem; 2013 Sep; 114(9):2120-30. PubMed ID: 23553841
[TBL] [Abstract][Full Text] [Related]
10. The roles of four multi-drug resistance proteins in hepatocellular carcinoma multidrug resistance.
Li G; Chen X; Wang Q; Xu Z; Zhang W; Ye L
J Huazhong Univ Sci Technolog Med Sci; 2007 Apr; 27(2):173-5. PubMed ID: 17497289
[TBL] [Abstract][Full Text] [Related]
11. Shp2 SUMOylation promotes ERK activation and hepatocellular carcinoma development.
Deng R; Zhao X; Qu Y; Chen C; Zhu C; Zhang H; Yuan H; Jin H; Liu X; Wang Y; Chen Q; Huang J; Yu J
Oncotarget; 2015 Apr; 6(11):9355-69. PubMed ID: 25823821
[TBL] [Abstract][Full Text] [Related]
12. Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents.
Jia H; Yang Q; Wang T; Cao Y; Jiang QY; Ma HD; Sun HW; Hou MX; Yang YP; Feng F
Biochim Biophys Acta; 2016 Jul; 1860(7):1417-30. PubMed ID: 27091611
[TBL] [Abstract][Full Text] [Related]
13. FBI-1 promotes cell proliferation and enhances resistance to chemotherapy of hepatocellular carcinoma in vitro and in vivo.
Fang F; Yang L; Tao Y; Qin W
Cancer; 2012 Jan; 118(1):134-46. PubMed ID: 21713761
[TBL] [Abstract][Full Text] [Related]
14. Upregulated HOXC8 Expression Is Associated with Poor Prognosis and Oxaliplatin Resistance in Hepatocellular Carcinoma.
Xu P; Zhang X; Ni W; Fan H; Xu J; Chen Y; Zhu J; Gu X; Yang L; Ni R; Chen B; Shi W
Dig Dis Sci; 2015 Nov; 60(11):3351-63. PubMed ID: 26123838
[TBL] [Abstract][Full Text] [Related]
15. Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1.
Qin J; Luo M; Qian H; Chen W
Gene; 2014 Apr; 538(2):342-7. PubMed ID: 24447717
[TBL] [Abstract][Full Text] [Related]
16. NRF2 SUMOylation promotes de novo serine synthesis and maintains HCC tumorigenesis.
Guo H; Xu J; Zheng Q; He J; Zhou W; Wang K; Huang X; Fan Q; Ma J; Cheng J; Mei W; Xing R; Cai R
Cancer Lett; 2019 Dec; 466():39-48. PubMed ID: 31546024
[TBL] [Abstract][Full Text] [Related]
17. Proteomic investigation of 5-fluorouracil resistance in a human hepatocellular carcinoma cell line.
Tong SW; Yang YX; Hu HD; An X; Ye F; Hu P; Ren H; Li SL; Zhang DZ
J Cell Biochem; 2012 May; 113(5):1671-80. PubMed ID: 22189913
[TBL] [Abstract][Full Text] [Related]
18. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
[TBL] [Abstract][Full Text] [Related]
19. Suppression of BCRP expression and restoration of sensitivity to chemotherapy in multidrug-resistant HCC cell line HEPG2/ADM by RNA interference.
Li H; Zhou S; Li T; Liu Z; Wu J; Zeng G; Liu C; Gong J
Hepatogastroenterology; 2012 Oct; 59(119):2238-42. PubMed ID: 23435138
[TBL] [Abstract][Full Text] [Related]
20. SUMOylation regulates LKB1 localization and its oncogenic activity in liver cancer.
Zubiete-Franco I; García-Rodríguez JL; Lopitz-Otsoa F; Serrano-Macia M; Simon J; Fernández-Tussy P; Barbier-Torres L; Fernández-Ramos D; Gutiérrez-de-Juan V; López de Davalillo S; Carlevaris O; Beguiristain Gómez A; Villa E; Calvisi D; Martín C; Berra E; Aspichueta P; Beraza N; Varela-Rey M; Ávila M; Rodríguez MS; Mato JM; Díaz-Moreno I; Díaz-Quintana A; Delgado TC; Martínez-Chantar ML
EBioMedicine; 2019 Feb; 40():406-421. PubMed ID: 30594553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
